

Special Issue

Contemporary Clinical Treatment Options and Outcomes of Aortic Valve Disease

Message from the Guest Editors

The aortic valve is not only anatomically located at the center of the heart, but the diseases of this valve are also becoming an important subject for cardiologists and surgeons. Although its function was generally thought to be entirely passive, contemporary investigations have brought completely new insight into the complex physiology of the aortic root, thus opening a new field related to the understanding, diagnosis, and treatment of aortic valve diseases. Since 1952, with the first Hufnagel aortic valve prosthesis implantation in descending thoracic aorta at Georgetown University, Washington DC, much has been accomplished in the field. Advances in science and technology, spanning from genetics and molecular biology to bioengineering and biotechnology, have opened new horizons in aortic valve disease diagnosis and treatment options. I believe that this Special Issue will help to clarify some important and current questions regarding clinical and surgical practice, and to induce inspiration and yield new insights into aortic valve disease science.

Guest Editors

Dr. Mladen J. Kocica

UC Clinical Centre of Serbia, Clinics for Cardiac Surgery, Belgrade, Serbia

Dr. Igor Rudez

Department of Cardiac and Transplant Surgery, Dubrava University Hospital, Zagreb, Croatia

Deadline for manuscript submissions

closed (31 March 2024)



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.4
CiteScore 2.6
Indexed in PubMed



mdpi.com/si/148659

*Journal of Cardiovascular
Development and Disease*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

mdpi.com/journal/

jcdd





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.4
CiteScore 2.6
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed,
PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 22.9 days after
submission; acceptance to publication is undertaken in 2.6
days (median values for papers published in this journal in
the first half of 2024).